TWi Biotechnology, Inc. (6610.TWO) Stock
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases; and NORA520, an oral prodrug, which is hydrolyzed to Brexanolone.
Valuation
Financials & Margins
Valuation & Return Ratios
Ownership
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; AC- 1101, which is in Phase Ib trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases; and NORA520, an oral prodrug, which is hydrolyzed to Brexanolone. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan. TWi Biotechnology, Inc. operates as a subsidiary of Xinchen Investment Company.
TWi Biotechnology, Inc. (6610.TWO) stock trades at $17.20 with a market capitalization of $3.85B. The stock is valued at a negative price-to-earnings (P/E) ratio of -50.90, reflecting a net loss over the last twelve months, price-to-book of 7.41. Over the past 52 weeks the stock has ranged between $12.85 and $57.20, and currently trades 69.9% below its 52-week high.
On profitability, TWi Biotechnology, Inc. generates a return on equity (ROE) of -80.24% (negative, reflecting a net loss).
Official website: www.twibiotech.com
TWi Biotechnology, Inc. (6610.TWO) — frequently asked questions
What is TWi Biotechnology, Inc. (6610.TWO) stock price today?
TWi Biotechnology, Inc. (6610.TWO) is currently trading at $17.20, down 62.57% today.
What is 6610.TWO P/E ratio?
TWi Biotechnology, Inc.'s P/E ratio is -50.90. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is 6610.TWO return on equity (ROE)?
TWi Biotechnology, Inc.'s return on equity (ROE) is -80.24%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is TWi Biotechnology, Inc.'s market cap?
TWi Biotechnology, Inc. has a market capitalization of $3.85B.
Does 6610.TWO pay a dividend?
TWi Biotechnology, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does 6610.TWO carry?
TWi Biotechnology, Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is 6610.TWO's profit margin?
TWi Biotechnology, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is 6610.TWO in?
TWi Biotechnology, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is 6610.TWO listed on?
TWi Biotechnology, Inc. trades on TWO under the ticker 6610.TWO.
What is 6610.TWO's 52-week range?
Over the last year TWi Biotechnology, Inc. has traded between $12.85 and $57.20.
Related Healthcare Stocks
Popular Stocks
Screens 6610.TWO currently matches
On the figures above, TWi Biotechnology, Inc. passes the filters for 8 of our ready-made screens, among them Low Debt Stocks, Day Losers Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.